Evidence map›Paper›PMID 24656524›Full record

Trial reportComprehensive psychiatry2014

Differential impact of anxiety symptoms and anxiety disorders on treatment outcome for psychotic depression in the STOP-PD study.

Simon J C Davies, Benoit H Mulsant, Alastair J Flint, Anthony J Rothschild, Ellen M Whyte, Barnett S Meyers, STOP PD Study Group

Abstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Comprehensive psychiatry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Simon J C DaviesCentre for Addiction and Mental Health, Toronto, Canada; Department of Psychiatry, University of Toronto, Toronto, Canada; Academic Unit of Psychiatry, University of Bristol, Bristol, UK.
Benoit H MulsantCentre for Addiction and Mental Health, Toronto, Canada; Department of Psychiatry, University of Toronto, Toronto, Canada. Electronic address: benoit.mulsant@camh.ca.
Alastair J FlintDepartment of Psychiatry, University of Toronto, Toronto, Canada; University Health Network, Toronto, Canada.
Anthony J RothschildUniversity of Massachusetts Medical School and University of Massachusetts, Worcester, MA, USA.
Ellen M WhyteWestern Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Barnett S MeyersWeill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY, USA.
STOP PD Study Group

Funding

WITHIN SUBJ VARIABILITY IN MEASUREMENTS DRUG METABOL ENZYMES IN HLTY SUBJM01RR000056 · NCRR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEVINE, ARTHUR S · 1985 to 2006
$29.2M
Acute Pharmacotherapy of Unipolar Psychotic DepressionU01MH062565 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WHYTE, ELLEN M · 2002 to 2015
$3.0M
Acute Pharmacotherapy of Unipolar Psychotic DepressionU01MH062624 · NIMH · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI ROTHSCHILD, ANTHONY J · 2002 to 2015
$2.9M
Complex Trials for Severe Geriatric Mood DisordersK24MH069430 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MULSANT, BENOIT H · 2004 to 2008
$601k
NCRR NIH HHS M01 RR000056NIMH NIH HHS K24 MH069430NIMH NIH HHS U01 MH062565NIMH NIH HHS U01 MH062624
6 · The paper itself

Abstract

backgroundThere are conflicting results on the impact of anxiety on depression outcomes. The impact of anxiety has not been studied in major depression with psychotic features ("psychotic depression").

aimsWe assessed the impact of specific anxiety symptoms and disorders on the outcomes of psychotic depression.

methodsWe analyzed data from the Study of Pharmacotherapy for Psychotic Depression that randomized 259 younger and older participants to either olanzapine plus placebo or olanzapine plus sertraline. We assessed the impact of specific anxiety symptoms from the Brief Psychiatric Rating Scale ("tension", "anxiety" and "somatic concerns" and a composite anxiety score) and diagnoses (panic disorder and GAD) on psychotic depression outcomes using linear or logistic regression. Age, gender, education and benzodiazepine use (at baseline and end) were included as covariates.

resultsAnxiety symptoms at baseline and anxiety disorder diagnoses differentially impacted outcomes. On adjusted linear regression there was an association between improvement in depressive symptoms and both baseline "tension" (coefficient=0.784; 95% CI: 0.169-1.400; p=0.013) and the composite anxiety score (regression coefficient = 0.348; 95% CI: 0.064-0.632; p=0.017). There was an interaction between "tension" and treatment group, with better responses in those randomized to combination treatment if they had high baseline anxiety scores (coefficient=1.309; 95% CI: 0.105-2.514; p=0.033). In contrast, panic disorder was associated with worse clinical outcomes (coefficient=-3.858; 95% CI: -7.281 to -0.434; p=0.027) regardless of treatment.

conclusionsOur results suggest that analysis of the impact of anxiety on depression outcome needs to differentiate psychic and somatic symptoms.

Indexed as

Antidepressive AgentsAntipsychotic AgentsAnxietyAnxiety DisordersBenzodiazepinesFemaleHumansLogistic ModelsMajor Depressive DisorderMaleMiddle AgedOlanzapinePsychotic DisordersSelective Serotonin Reuptake InhibitorsSertralineTreatment OutcomeAntidepressive AgentsAntipsychotic AgentsBenzodiazepinesOlanzapineSelective Serotonin Reuptake InhibitorsSertraline

Identifiers

PMID24656524
PMCPMC4078996

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.